Clinical Trial Update: A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

This phase I/II trial evaluated a combination of liposomal doxorubicin, melphalan, and bortezomib in relapsed/refractory multiple myeloma, but the study has bee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Doxil (liposomal doxorubicin)
• Melphalan (Melphalan)
• Velcade (bortezomib)

Snippet

Sponsor: University of California, San Francisco | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: WITHDRAWN